<table id="ic07921ff-af34-41d4-8888-ecdadacb6235" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<thead>
<tr>
<th colspan="4">
                    Table 1. Select Mean (±S.D) Metformin
                    Pharmacokinetic Parameter Following<br/>Single or Multiple Oral Doses of
                    Metformin Hydrochloride Tablets, USP
                  </th>
</tr>
<tr>
<th>
                    Subject Groups:<br/>Metformin dose<sup>a</sup>
<br/>(number of subjects)
                  </th>
<th>
                    C<sub>max</sub>
<sup>b</sup>
<br/>(µg/mL)
                  </th>
<th>
                    T<sub>max</sub>
<sup>c</sup>
<br/>(hrs)
                  </th>
<th>
                    Renal
                    Clearence<br/>(mL/min)
                  </th>
</tr>
</thead>
<tbody>
<tr>
<td>
<sup>a</sup>-All doses given fasting except the first
                    18 doses of the multiple dose studies;<br/>
<sup>b</sup>-Peak plasma
                    concentration;<br/>
<sup>c</sup>-Time to peak plasma
                    concentration;<br/>
<sup>d</sup>-Combined results (average means) of
                    five studies: mean age 32 years (range 23-59 yrs).<br/>
<sup>e</sup>-Kinetic study, done following dose 19, given
                    fasting.<br/>
<sup>f</sup>-Elderly subjects, mean age 71 years (range
                    65-81 years).<br/>
<sup>g</sup>-CL<sub>cr</sub> =
                    creatinine clearance normalized to body surface area of 1.73 m<sup>2</sup>.<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">
                      Healthy, nondiabetic
                      adults:
                    </content>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>500 mg single dose (24)</td>
<td>1.03 (±0.33)</td>
<td>2.75 (±0.81)</td>
<td>600 (±132)</td>
</tr>
<tr>
<td>
                    850 mg single dose (74)<sup>d</sup>
</td>
<td>1.60 (±0.38)</td>
<td>2.64 (±0.82)</td>
<td>552 (±139)</td>
</tr>
<tr>
<td>
                    850 mg three times daily for 19
                    doses<sup>e</sup> (9)
                  </td>
<td>2.01 (±0.42)</td>
<td>1.79 (±0.94)</td>
<td>642 (±173)</td>
</tr>
<tr>
<td>
<content stylecode="bold">
                      Adults with type 2
                      diabetes:
                    </content>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>850 mg single dose (23)</td>
<td>1.48 (±0.5)</td>
<td>3.32 (±1.08)</td>
<td>491 (±138)</td>
</tr>
<tr>
<td>
                    850 mg three times daily for 19
                    doses<sup>e</sup> (9)
                  </td>
<td>1.90 (±0.62)</td>
<td>2.01 (±1.22)</td>
<td>550 (±160)</td>
</tr>
<tr>
<td>
<content stylecode="bold">
                      Elderly<sup>f</sup>, healthy nondiabetic adults:
                    </content>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>850 mg single dose (12)</td>
<td>2.45 (±0.70)</td>
<td>2.71 (±1.05)</td>
<td>412 (±98)</td>
</tr>
<tr>
<td>
<content stylecode="bold">
                      Renal-impaired
                      adults:
                    </content>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>850 mg single dose</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>
                    Mild (CL<sub>cr</sub>g
                    61-90 mL/min) (5)
                  </td>
<td>1.86 (±0.52)</td>
<td>3.20 (±0.45)</td>
<td>384 (±122)</td>
</tr>
<tr>
<td>
                    Moderate (CL<sub>cr</sub>
                    31-60 mL/min) (4)
                  </td>
<td>4.12 (±1.83)</td>
<td>3.75 (±0.50)</td>
<td>108 (±57)</td>
</tr>
<tr>
<td>
                    Severe (CL<sub>cr</sub>
                    10-30 mL/min) (6)
                  </td>
<td>3.93 (±0.92)</td>
<td>4.01 (±1.10)</td>
<td>130 (±90)</td>
</tr>
</tbody>
</table>